Pfizer managed to disappoint just about everyone this morning with its full-year outlook as generic competition eats into their big franchise revenue streams. For a company that has long prided itself on the numbers, it was a telling setback that follows a wide-ranging reorganization plan that is culling staff and eliminating segments of R&D. Shares were down close to 3% Tuesday morning, ahead of the opening bell.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,700+ biopharma pros who read Endpoints News by email every day.Free Subscription